Search PubMed⌕ Search

Biomedical subjects

I C Shaw

Publications and source records attributed to I C Shaw.

At least 37 records · Page 2Linked to original sources
PubMed1993

In vitro studies on the metabolism of antipyrine in the pig and rat: with special reference to veterinary medicine licensing.

Preparation of product licence applications for veterinary medicines requires metabolic studies in the target species. This experimental procedure uses animals and is costly. In the present report of preliminary studies it is demonstrated that pig liver homogenates prepared from abattoir material and homogenates of rat liver show the interspecies metabolic differences that would be expected in vivo. The results therefore support the use of abattoir-derived liver homogenates in preliminary studies to investigate target species metabolism in veterinary drug development.

Animals↗
PubMed1990

Preferential distribution of streptomycin in pig kidney cortex.

In 14 pig kidneys containing streptomycin, an average distribution ratio of 2.5:1 was found for the streptomycin between the cortex and medulla. It is suggested here that cortex alone be used, instead of mixed kidney tissue, in regulatory meat monitoring schemes.

Animals↗
PubMed1987

Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.

Dimesna was given to volunteers (n = 6) and levels of free thiols, mesna, cysteine and disulphides measured in urine. Mesna is excreted in the urine following oral dimesna administration. Peak urinary free thiol levels occur between 10 and 20 hr. Cysteine and mixed disulphides are also excreted. Mesna might be useful in prolonged bladder protection during oxazaphosphorine cancer chemotherapy.

Administration, Oral↗
PubMed1986

The fate of [14C]-mesna in the rat.

[14C]-Mesna (sodium 2-mercaptoethanesulphonate) has a short serum t1/2 (about 16.5 min) and is excreted in the urine. Within 24 h approx. 77% of the administered dose appeared in the urine. It is bound to serum albumin and immunoglobulins. Total serum protein binding is about 9.7% of the total amount present in serum. [14C]-mesna + [14C]-dimesna (bis[2-mercaptoethane sulphonate]) are present in the blood stream, and so are found in the body organs at low concentration, however, localisation of radioactivity occurs in the kidneys. The binding of [14C]-mesna to proteins and the localisation of [14C]-mesna or [14C]-dimesna in the kidneys are discussed in the context of the cell killing efficacy of the oxazaphosphorines.

Animals↗
PubMed1986

Interaction between mesna and selected transition metals in vitro and in vivo.

The interactions between mercaptoethanesulphonic acid (mesna) and transition metal ions was investigated. Mesna was shown to react with selected transition metals (to form covalent metal thiol compounds) resulting in reduction of their oxidation state with the possible concomitant oxidation of mesna to dimesna. The reactions between mesna and copper were investigated in detail. Mesna is known to bind to serum albumin, copper was found to chemically combine with the mesna protein complex. Administration of copper to rats resulted in accumulation of copper in the kidney, while simultaneous administration of mesna and copper resulted in accumulation of copper in liver. The possible role of mesna-albumin complexes in copper transport is postulated and the importance of this in cancer treatment, where serum copper levels are often raised, is discussed.

Albumins↗
PubMed1985

Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.

Sodium 2-mercaptoethanesulphonate (MESNA) is a uroprotective agent generally given i.v. to prevent haemorrhagic cystitis during oxazaphosphorine cancer chemotherapy. Oral administration of the drug is described since this might be an important route during long-term oxazaphosphorine treatment. MESNA is absorbed from the GI tract and excreted in the urine (about 41.5% of the dose), peak excretion being 2-3 hr after administration. A proportion of the excreted dose is as free thiols (about 24.2%) and the remainder is as disulphides. MESNA is shown to enhance excretion of cysteine in urine.

Administration, Oral↗